James Nokes/Vaccine

Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach.Pan-Ngum, W. Kinyanjui, T. Kiti, M. Taylor, S. Toussaint, J. F. Saralamba, S. Van Effelterre, T. Nokes, D. J. White, L. J.
Vaccine, (2017). 35:403-409

Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya.Nyiro, J. U. Sande, C. Mutunga, M. Kiyuka, P. K. Munywoki, P. K. Scott, J. A. Nokes, D. J.
Vaccine, (2015). 33:1797-801

The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants.Sande, C. J. Cane, P. A. Nokes, D. J.
Vaccine, (2014). 32:4726-9

Strategic priorities for respiratory syncytial virus (RSV) vaccine development.Anderson, L. J. Dormitzer, P. R. Nokes, D. J. Rappuoli, R. Roca, A. Graham, B. S.
Vaccine, (2013). 31 Suppl 2:B209-15

Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules.Wilson, J. N. Nokes, D. J. Medley, G. F. Shouval, D.
Vaccine, (2007). 25:3705-12